Logo

American Heart Association

  117
  0


Final ID: Mo4169

Isolated Tricuspid Replacement versus Repair among Medicare Beneficiaries

Abstract Body (Do not enter title and authors here): Background: Evidence is limited regarding mid-term outcomes following isolated tricuspid operations for tricuspid regurgitation at the population level.
Objective: This study aimed to compare the mid-term outcomes following isolated tricuspid valve replacement versus repair using contemporary data.
Methods: We analyzed the national data on Medicare beneficiaries aged ≥65 who underwent isolated tricuspid valve replacement or repair between January 2016 and December 2020. The primary outcome was mid-term (up to 3 years) all-cause mortality. The secondary outcomes included mid-term major adverse cardiovascular events (MACE) and heart failure hospitalizations, as well as in-hospital permanent pacemaker implantation rates. MACE comprised all-cause mortality, heart failure hospitalization, stroke, and tricuspid reoperations. A propensity score-matching analysis was conducted to compare the two groups.
Results: A total of 1,693 patients were included (replacement= 655 patients, repair= 1,038 patients). In the matched cohort (597 patients in each group), the overall mortality and MACE were 40% and 47% at 3 years, respectively. Tricuspid valve replacement was associated with similar all-cause mortality in comparison to repair (adjusted hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.95-1.39; P=0.15). Similarly, the rates of MACE and heart failure hospitalizations were similar (adjusted HR, 1.10; 95% CI, 0.93-1.32, P=0.27; subdistribution HR, 1.07, 95% CI, 0.75-1.54, P=0.69, respectively) between these two procedures. Patients undergoing replacement required permanent pacemaker implantations more frequently (25.4% vs. 12.4%; P<0.001).
Conclusions: Isolated surgical tricuspid valve replacement was associated with similar clinical outcomes compared to repair, except for permanent pacemaker implantation rates. The overall high mid-term mortality and morbidity with either treatment highlight the need for better options and further research to optimize the indication and timing of intervention.
  • Shimoda, Tomonari  ( University of Tsukuba Hospital , Tsukuba City, Ibaraki , Japan )
  • Kuno, Toshiki  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Tsugawa, Yusuke  ( David Geffen School of Medicine at UCLA , Los Angeles , California , United States )
  • Ueyama, Hiroki  ( Emory University School of Medicine , Atlanta , Georgia , United States )
  • Miyamoto, Yoshihisa  ( University of Tokyo , Tokyo , Tokyo , Japan )
  • Watanabe, Atsuyuki  ( Mount Sinai Morningside and West , New York , New York , United States )
  • Gotanda, Hiroshi  ( Cedars-Sinai Medical Center , Los Angeles , California , United States )
  • Elmariah, Sammy  ( Univ California, San Francisco , San Francisco , California , United States )
  • Yokoyama, Yujiro  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Fukuhara, Shinichi  ( University of Michigan , Ann Arbor , Michigan , United States )
  • Kaneko, Tsuyoshi  ( Washington University in St. Louis , St. Louis , Missouri , United States )
  • Author Disclosures:
    Tomonari Shimoda: DO NOT have relevant financial relationships | Toshiki Kuno: DO NOT have relevant financial relationships | Yusuke Tsugawa: DO NOT have relevant financial relationships | Hiroki Ueyama: DO NOT have relevant financial relationships | Yoshihisa Miyamoto: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):DeSC Healthcare:Active (exists now) | Atsuyuki Watanabe: DO NOT have relevant financial relationships | Hiroshi Gotanda: DO NOT have relevant financial relationships | Sammy Elmariah: DO have relevant financial relationships ; Research Funding (PI or named investigator):Edwards Lifesciences:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:Edwards Lifesciences:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) | Yujiro Yokoyama: DO NOT have relevant financial relationships | Shinichi Fukuhara: No Answer | Tsuyoshi Kaneko: DO have relevant financial relationships ; Advisor:Edwards Lifesciences:Active (exists now) ; Advisor:Johnson and Johnson:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Advisor:Abbott:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Advanced Approaches in Valvular Disease: From Biomechanics to Clinical Practice

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
9-Year Longitudinal Assessment of the 12-lead Electrocardiogram of Volunteer Firefighters

Bae Alexander, Dzikowicz Dillon, Lai Chi-ju, Brunner Wendy, Krupa Nicole, Carey Mary, Tam Wai Cheong, Yu Yichen

A Pressure-Volume Loops Approach Predicts Outcomes After Double Switch Operation For Congenitally Corrected Transposition Of The Great Arteries with Intact Ventricular Septum

Thatte Nikhil, Del Nido Pedro, Ghelani Sunil, Hammer Peter, Marx Gerald, Beroukhim Rebecca, Gauvreau Kimberlee, Callahan Ryan, Prakash Ashwin, Emani Sitaram, Hoganson David

More abstracts from these authors:
Free Right Internal Mammary Artery vs In-situ Right Internal Mammary Artery as a Second Conduit for Coronary Artery Bypass Surgery: A Meta-Analysis

Kikuchi Yuta, Pompeu Sa Michel, Kuno Toshiki, Sakata Tomoki, Shimoda Tomonari, Fukuhara Shinichi, Shimamura Junichi, Hibino Makoto, Kaneko Tsuyoshi, Takayama Hiroo, Takagi Hisato

Transcatheter versus Surgical Tricuspid Repair among Medicare Beneficiaries: One-Year Results

Shimoda Tomonari, Ueyama Hiroki, Miyamoto Yoshihisa, Watanabe Atsuyuki, Gotanda Hiroshi, Tsugawa Yusuke, Kuno Toshiki

You have to be authorized to contact abstract author. Please, Login
Not Available